362 related articles for article (PubMed ID: 22177248)
21. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
22. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms.
Mounajjed T; Zhang L; Wu TT
Hum Pathol; 2013 Apr; 44(4):542-50. PubMed ID: 23079207
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
Ibrahim TR; Abdel-Raouf SM
Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic accuracy of glypican-3 in differentiating hepatocellular carcinoma from metastatic liver tumours.
Majeed S; Mushtaq S; Azam M; Akhtar N; Hussain M; Loya A
J Pak Med Assoc; 2018 Jul; 68(7):1029-1031. PubMed ID: 30317296
[TBL] [Abstract][Full Text] [Related]
25. [Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma].
Bian YZ; Yao DF; Zhang CG; Li SS; Wu W; Dong ZZ; Qiu LW; Yu DD
Zhonghua Gan Zang Bing Za Zhi; 2011 Apr; 19(4):260-5. PubMed ID: 21586223
[TBL] [Abstract][Full Text] [Related]
26. Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis.
Sun B; Huang Z; Wang B; Yu Y; Lin S; Luo L; Wang Y; Huang Z
Med Sci Monit; 2017 Feb; 23():850-855. PubMed ID: 28207681
[TBL] [Abstract][Full Text] [Related]
27. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
[TBL] [Abstract][Full Text] [Related]
28. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy.
Anatelli F; Chuang ST; Yang XJ; Wang HL
Am J Clin Pathol; 2008 Aug; 130(2):219-23. PubMed ID: 18628090
[TBL] [Abstract][Full Text] [Related]
29. [Glypican 3 expression in hepatoblastoma and its diagnostic implication].
Wang FH; Wen JM; Vong HT; Yip YC
Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):806-9. PubMed ID: 24507097
[TBL] [Abstract][Full Text] [Related]
30. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm.
Wang F; Jing X; Wang T; Li G; Li T; Zhang Q; Huang Y; Li J; Wang Y; Gao Y; Han T; Du Z
Am J Clin Pathol; 2012 Jun; 137(6):937-45. PubMed ID: 22586053
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy.
Wang FH; Yip YC; Zhang M; Vong HT; Chan KI; Wai KC; Wen JM
J Clin Pathol; 2010 Jul; 63(7):599-603. PubMed ID: 20501450
[TBL] [Abstract][Full Text] [Related]
32. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
[TBL] [Abstract][Full Text] [Related]
33. A triple stain of reticulin, glypican-3, and glutamine synthetase: a useful aid in the diagnosis of liver lesions.
Swanson BJ; Yearsley MM; Marsh W; Frankel WL
Arch Pathol Lab Med; 2015 Apr; 139(4):537-42. PubMed ID: 25822763
[TBL] [Abstract][Full Text] [Related]
34. [Relationship between glypican-3 and Notch1 expressions in hepatocellular carcinoma].
Peng F; Wu Z; Li X
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Apr; 33(4):590-2, 597. PubMed ID: 23644127
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
36. A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values.
Jin GZ; Dong H; Yu WL; Li Y; Lu XY; Yu H; Xian ZH; Dong W; Liu YK; Cong WM; Wu MC
BMC Cancer; 2013 Mar; 13():161. PubMed ID: 23537217
[TBL] [Abstract][Full Text] [Related]
37. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.
Cai MY; Tong ZT; Zheng F; Liao YJ; Wang Y; Rao HL; Chen YC; Wu QL; Liu YH; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
Gut; 2011 Jul; 60(7):967-76. PubMed ID: 21330577
[TBL] [Abstract][Full Text] [Related]
38. Quantification of glypican 3, β-catenin and claudin-1 protein expression in hepatoblastoma and paediatric hepatocellular carcinoma by colour deconvolution.
Zhou S; Parham DM; Yung E; Pattengale P; Wang L
Histopathology; 2015 Dec; 67(6):905-13. PubMed ID: 25939253
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
[TBL] [Abstract][Full Text] [Related]
40. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients.
Jeon Y; Kim H; Jang ES; Hong S; Kim JW; Yoon YS; Cho JY; Han HS; Jeong SH
APMIS; 2016 Mar; 124(3):208-15. PubMed ID: 26764243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
